Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Ref Type | Journal Article | ||||||||||||
PMID | (20610623) | ||||||||||||
Authors | Ewan K, Pajak B, Stubbs M, Todd H, Barbeau O, Quevedo C, Botfield H, Young R, Ruddle R, Samuel L, Battersby A, Raynaud F, Allen N, Wilson S, Latinkic B, Workman P, McDonald E, Blagg J, Aherne W, Dale T | ||||||||||||
Title | A useful approach to identify novel small-molecule inhibitors of Wnt-dependent transcription. | ||||||||||||
|
|||||||||||||
URL | |||||||||||||
Abstract Text | The Wnt signaling pathway is frequently deregulated in cancer due to mutations in genes encoding APC, beta-catenin, and axin. To identify small-molecule inhibitors of Wnt signaling as potential therapeutics, a diverse chemical library was screened using a transcription factor reporter cell line in which the activity of the pathway was induced at the level of Disheveled protein. A series of deconvolution studies was used to focus on three compound series that selectively killed cancer cell lines with constitutive Wnt signaling. Activities of the compounds included the ability to induce degradation of beta-catenin that had been stabilized by a glycogen synthase kinase-3 (GSK-3) inhibitor. This screen illustrates a practical approach to identify small-molecule inhibitors of Wnt signaling that can seed the development of agents suitable to treat patients with Wnt-dependent tumors. |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
CCT031374 | CCT031374 | 1 | 0 |
CCT036477 | CCT036477 | 1 | 0 |
CCT070535 | CCT070535 | 1 | 0 |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CCT031374 | CTNNB1 Inhibitor 27 | CCT031374 inhibits TCF/CTNNB1 dependent transcription thereby blocking Wnt signaling, which results in apoptosis (PMID: 20610623, PMID: 26496941). | ||
CCT036477 | CCT-036477 | CTNNB1 Inhibitor 27 | CCT036477 inhibits TCF/CTNNB1 dependent transcription thereby blocking Wnt signaling, which results in apoptosis (PMID: 20610623, PMID: 26522223). | |
CCT070535 | CTNNB1 Inhibitor 27 | CCT070535 inhibits TCF/CTNNB1 dependent transcription thereby blocking Wnt signaling, which results in apoptosis (PMID: 20610623). |
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
APC inact mut | colorectal cancer | sensitive | CCT031374 | Preclinical | Actionable | In a preclinical study, CCT031374 inhibited Wnt pathway activation and growth of colorectal cancer cell lines harboring APC inactivating mutations in culture (PMID: 20610623). | 20610623 |
APC inact mut | colorectal cancer | sensitive | CCT036477 | Preclinical | Actionable | In a preclinical study, CCT036477 inhibited Wnt pathway activation and growth of colorectal cancer cell lines harboring APC inactivating mutations in culture (PMID: 20610623). | 20610623 |
APC inact mut | colorectal cancer | sensitive | CCT070535 | Preclinical | Actionable | In a preclinical study, CCT070535 inhibited Wnt pathway activation and growth of colorectal cancer cell lines harboring APC inactivating mutations in culture (PMID: 20610623). | 20610623 |